SCHEMBL216676

SCHEMBL216676

CC(C)(O[Si](C)(C)C)c1ccnc(-c2ccc3nc(-c4n[nH]c5ccccc45)cn3c2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 5/20 0.38
PIM1 P11309 6/20 0.36
PIM3 Q86V86 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
ROCK2 O75116 2/20 0.34
MAP4K4 O95819 2/20 0.34
CDK2 P24941 2/20 0.34
HIPK2 Q9H2X6 2/20 0.34
IRAK4 Q9NWZ3 2/20 0.34
PLK4 O00444 1/20 0.34
CHEK1 O14757 1/20 0.34
AURKA O14965 1/20 0.34
CHUK O15111 1/20 0.34
PDPK1 O15530 1/20 0.34
JAK2 O60674 1/20 0.34
PAK4 O96013 1/20 0.34
CHEK2 O96017 1/20 0.34
ABL1 P00519 1/20 0.34
NTRK1 P04629 1/20 0.34
PRKCG P05129 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL216882 0.87 NR4A2 (0.45) LRRK2PIM1PIM3PIM2ROCK2
SCHEMBL3432224 0.74 NR4A2 (0.61) ROCK2MAP4K4CDK2HIPK2IRAK4
SCHEMBL217078 0.71 HTR6 (0.45) KDM4EMEN1NPC1RAB9AKMT2A
SCHEMBL218442 0.64 NR4A2 (0.47) SYKKDM4EMEN1NPC1MAPT
SCHEMBL3431991 0.64 NR4A2 (0.49) LRRK2ABL1KDM4EMEN1NPC1
SCHEMBL3433416 0.63 NR4A2 (0.62) LRRK2PIM1ROCK2MAP4K4CDK2
SCHEMBL218150 0.62 NR4A2 (0.46) KDM4EMEN1NPC1MAPTRAB9A
SCHEMBL12781223 0.62 CYP2A6 (0.37) ABL1CSF1RFLT3SYK
SCHEMBL17886006 0.60 IDO1 (0.65) LRRK2ROCK2MAP4K4CDK2HIPK2
SCHEMBL1328336 0.59 LRRK2 (1.00) LRRK2PIM1PIM3PIM2AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262804-B1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-12-03 EP disclosed
US-8598166-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2013-12-03 US disclosed
US-20120053202-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2012-03-01 US disclosed
US-8088765-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-01-03 US disclosed
US-20110065700-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed
EP-2262804-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-aventis (FR) 2010-12-22 EP disclosed
WO-2009144392-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065700-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF CYP4X1, HAX1, JAK2 LRRK2 2114/4885PIM1 3333/4885PIM3 3680/4885
US-20120053202-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF CYP4X1, HAX1, JAK2 LRRK2 2114/4885PIM1 3333/4885PIM3 3680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.